Motley Fool • 2 days ago
To find out which big pharma stock is the better pick right now, we'll see how Eli Lilly and GlaxoSmithKline stack up to each other.
Zacks • 4 days ago
Bayer AG's (BAYRY) fourth-quarter 2016 core earnings increased 10.2% year over year to ???1.19 per share (approximately $1.28). Reported earnings missed the Zacks Consensus Estimate of $1.37.
Zacks • 5 days ago
Pfizer Inc. (PFE) announced that its Biologics License Application (BLA) for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA.
Investor's Business Daily • 5 days ago
Gilead and GSK will have a tough time divorcing HIV patients from their traditional three-pill regimens, Leerink said Wednesday,
Barrons.com • 5 days ago
The Conference on Retroviruses and Opportunistic Infections (CROI) Annual Meeting took place last week, and while this meeting is one of the most important for HIV treatment data, it's closed to investors and non-clinicians. As such, Leerink's Geoffrey Porges and Bradley Canino hosted a call with two specialists in HIV treatment, to discuss their impressions of the meeting. Specifically, they discussed the specialists' reactions to Gilead's (GILD) bictegravir, GlaxoSmithKline's (GSK) dolutegravir two-drug combinations, and Merck's (MRK) doravirine, as well as Gilead's tenofovir alafenamide fumarate (TAF) adoption in the US and Europe.
Zacks • 11 days ago
Zoetis Inc. (ZTS) topped earnings estimates in the fourth-quarter of 2016 while revenues came in line. The company also narrowed its outlook for 2017 to account for currency impact.
GSK : Summary for GlaxoSmithKline PLC Common Stoc - Yahoo Finance
GlaxoSmithKline plc (GSK)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||41.21 - 41.61|
|52 Week Range||37.20 - 45.58|
|PE Ratio (TTM)||89.67|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Dividend & Yield||2.00 (4.82%)|
|1y Target Est||47.00|